One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1136/annrheumdis-2022-eular.1377
Copy DOI Journal: Annals of the Rheumatic Diseases |  Publication Date: May 23, 2022 |
 Citations: 6 |
Affiliation: Oregon Medical Research Center, Probity Medical Research, Queen's University, University of Southern California, Veracity Clinical Research, University of California, Los Angeles, University Hospitals of Cleveland, Case Western Reserve University, Bristol-Myers Squibb (United States), Fukuoka University Hospital, University of Lübeck, Second Affiliated Hospital of Zhejiang University, Central Dermatology, Yale UniversityAB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
